Home News

News

SOTIO and NBE-Therapeutics to Develop ‘Second’ Next-Generation Antibody-Drug Conjugate

SOTIO, a biotechnology company leading the efforts of PPF Group, one of the largest investment groups in Central and...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Loncastuximab Tesirine Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Loncastuximab tesirine, also known as ADCT-402, an investigational antibody-drug conjugate being developed by ADC Therapeutics, showed signs of clinical...
Daiichi Sankyo

Daiichi Sankyo to Defend Proprietary Antibody-drug Conjugate Technology

Daiichi Sankyo confirmed that the company has filed a Declaratory Judgement action in the District Court of Delaware in...
Featured Image: Boston Public Garden; Boston, MA. Courtesy: © 2017 Fotolia. Used with permission.

Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 in Patients with...

Initial safety data of STRO-002 shows potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models were presented...
Daiichi Sankyo, Basking Ridge, NJ. Courtesy: Daiichi Sankyo.

Daiichi Sankyo Starts First-in-Human Phase I/II Study Evaluating DS-7300

Daiichi Sankyo, in collaboration with and Sarah Cannon Research Institute, has started the first-in-human, open label, phase I/II study...
Gesso Italiano (Italian Chalk) in San Diego's Little Italy neighborhood celebrating its heritage by bringing the vibrancy and flavors of Italy to southern California. Courtesy: 2016 Fotolia.

Advanced Design of ADCs: Principles and Applications using Next Generation Linkers and Site-Specific Technology

Over the years there have been major challenges in the development of antibody-drug conjugates (ADC), including: choosing the right...
Signing Ceremony between Ambrx an NovoCodex. Courtesy 2019 NovoCodex.

Ambrx and Novocodex to Jointly Develop and Commercialize 2nd Antibody-drug Conjugate

Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and  Ambrx, a privately-held clinical stage biopharmaceutical company, have confirmed that the...

Immunome and pH Pharma Sign Agreement for the Development of Novel ADCs

South Korea-based pH Pharma, a clinical stage biopharmaceutical company and U.S.-based Immunome, a biotechnology company developing first-in-class antibodies as...

What’s New in ADCs this Week – Oct 21st, 2019

Hello all,It's been a full month since the last update already, which means there is a big backlog of...
On October 16, 2019 Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and WuXi Biologics signed a strategic partnership for Phase III clinical trial production of ARX788 as well ongoing large-scale commercial production of the innovative antibody-drug conjugate.

WuXi Biologics Opens New Facility to Supports Novocodex ADC Manufacturing

Earlier this month China-based Contract Research Organization (CRO) WuXi Biologics started commercial production at the company's new Current Good...